Aytu BioPharma, Inc. (AYTU)
| Market Cap | 27.37M |
| Revenue (ttm) | 62.64M |
| Net Income (ttm) | -24.44M |
| Shares Out | 10.73M |
| EPS (ttm) | -3.02 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 8,959 |
| Open | 2.520 |
| Previous Close | 2.560 |
| Day's Range | 2.470 - 2.550 |
| 52-Week Range | 1.060 - 3.065 |
| Beta | 0.28 |
| Analysts | Strong Buy |
| Price Target | 9.33 (+265.88%) |
| Earnings Date | May 13, 2026 |
About AYTU
Aytu BioPharma, Inc., a pharmaceutical company, focuses on commercializing novel therapeutics in the United States and internationally. The company offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT extended-release orally disintegrating tablets for patients from six years of age and above; Cotempla XR-ODT extended-release orally disintegrating tablets for patients from six to seventeen years old; and Metadate CD, a central nervous system stimulant indicated for the treatm... [Read more]
Financial Performance
In fiscal year 2025, Aytu BioPharma's revenue was $66.38 million, an increase of 1.84% compared to the previous year's $65.18 million. Losses were -$13.56 million, -14.40% less than in 2024.
Financial StatementsAnalyst Forecast
According to 3 analysts, the average rating for AYTU stock is "Strong Buy." The 12-month stock price target is $9.33, which is an increase of 265.88% from the latest price.
News
Aytu BioPharma Earnings Call Transcript: Q2 2026
Exxua's commercial launch showed strong early adoption, with over 100 prescribers in 27 states and positive patient feedback, while ADHD and pediatric revenues remained stable amid generic competition. Net revenue was $15.2M, with a net loss of $10.6M due to launch investments and non-cash warrant losses.
Aytu BioPharma Reports Fiscal 2026 Second Quarter Operational and Financial Results
Total net revenue of $15.2 million Adjusted EBITDA1 of $(0.8) million, which includes EXXUA launch investments $30.0 million cash balance at December 31, 2025 Company launched EXXUA™ (gepirone) extend...
Aytu BioPharma to Report Fiscal 2026 Second Quarter Operational and Financial Results on February 3, 2026
DENVER, CO / ACCESS Newswire / January 27, 2026 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central n...
Aytu BioPharma Recaps Investor Day Held on January 20, 2026
DENVER, CO / ACCESS Newswire / January 20, 2026 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central n...
Aytu BioPharma Transcript: Investor Day 2026
Exxua, a first-in-class 5-HT1A agonist for MDD, launches nationally with a focus on early patient benefit, strong tolerability, and efficient commercial execution. The company’s disciplined financial strategy aligns costs with performance, supporting sustainable growth and profitability.
Aytu BioPharma Transcript: 2nd Annual Lytham Partners Healthcare Investor Summit
Exxua, a novel antidepressant, is being launched through a strategic partnership, leveraging an established psychiatry-focused sales force and the RxConnect pharmacy network to address market access and differentiation. The legacy ADHD business remains stable despite generic competition, and management expects Exxua to drive significant revenue growth in a much larger market.
Aytu BioPharma to Participate in the Lytham Partners 2026 Investor Healthcare Summit on January 15, 2026
DENVER, CO / ACCESS Newswire / January 13, 2026 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central n...
Aytu BioPharma Details Agenda for Investor Day Scheduled for January 20, 2026 in New York City
DENVER, CO / ACCESS Newswire / January 12, 2026 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central n...
Aytu BioPharma to Host Investor Day on January 20, 2026 in New York City
DENVER, CO / ACCESS Newswire / December 18, 2025 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central ...
Aytu BioPharma Announces Commercial Availability of EXXUA(TM) (gepirone) Extended-Release Tablets, the First and Only 5HT1a Agonist Indicated for the Treatment of Major Depressive Disorder in Adults
EXXUA is now available through Aytu RxConnect® pharmacies to ensure optimal access and availability EXXUA has demonstrated significant improvement in depression symptoms in clinical trials involving m...
Aytu BioPharma to Participate in Noble Capital Markets 21st Annual Emerging Growth Equity Conference
DENVER, CO / ACCESS Newswire / November 24, 2025 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central ...
Aytu BioPharma Earnings Call Transcript: Q1 2026
Net revenue reached $13.9 million, with ADHD portfolio growth offsetting declines in pediatrics. Exxua launch preparations are on track for late 2025, supported by strong patent protection and targeted market access strategies. Cash position remains strong at $32.6 million.
Aytu BioPharma Reports Fiscal 2026 First Quarter Operational and Financial Results
Total net revenue of $13.9 million Net income of $2.0 million, or $0.21 net income per share basic Adjusted EBITDA1 of $(0.6) million, which includes EXXUA launch investments $32.6 million cash balanc...
Aytu BioPharma to Report Fiscal 2026 First Quarter Operational and Financial Results on November 13, 2025
DENVER, CO / ACCESS Newswire / November 5, 2025 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central n...
Aytu BioPharma Announces Patent Term Extension for EXXUA(TM)
DENVER, CO / ACCESS Newswire / October 28, 2025 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central n...
Aytu BioPharma Transcript: Planet MicroCap Showcase: TORONTO 2025
After a major transformation, the company is now focused on CNS therapeutics, with stable ADHD revenues and the upcoming launch of Exxua for MDD. Exxua's unique side effect profile and large market potential underpin growth plans, supported by a streamlined cost structure and experienced management.
Aytu BioPharma to Present at Upcoming October 2025 Conferences
DENVER, CO / ACCESS Newswire / October 10, 2025 /Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central ne...
Aytu BioPharma Transcript: Lytham Partners Fall 2025 Investor Conference
A strategic realignment has led to a profitable, focused prescription business with a strong ADHD portfolio and the upcoming launch of Exxua, a novel antidepressant. Exxua’s unique profile and robust commercial infrastructure position the company for significant growth in the large depression market.
Aytu BioPharma Transcript: MicroCap Rodeo Fall Conference
A specialty pharma firm is preparing to launch Exxua, a novel MDD treatment with a unique side effect profile, aiming for significant market adoption by mid-2026. Strong psychiatrist interest, robust financials, and a focused strategy support growth plans.
Aytu BioPharma to Present at Upcoming September 2025 Conferences
DENVER, CO / ACCESS Newswire / September 24, 2025 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central...
Aytu BioPharma Earnings Call Transcript: Q4 2025
Fiscal 2025 delivered stable revenue and positive adjusted EBITDA, with the company preparing for the transformative launch of Exua, a novel MDD treatment, by year-end. ADHD and pediatric portfolios remain margin positive, while a strong cash position supports upcoming investments.
Aytu BioPharma Reports Fiscal 2025 Full Year and Fourth Quarter Operational and Financial Results and Outlines Commercial Launch Plans for EXXUA(TM)
Full year fiscal 2025 net revenue of $66.4 million Full year fiscal 2025 net loss of $13.6 million Full year fiscal 2025 adjusted EBITDA1 of $9.2 million $31.0 million cash balance at June 30, 2025 Ex...
Aytu BioPharma to Report Fiscal 2025 Full Year and Fourth Quarter Operational and Financial Results on September 23, 2025
DENVER, CO / ACCESS Newswire / September 16, 2025 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central...
Aytu BioPharma Appoints Dr. Gerwin Westfield as Senior Vice President of Scientific Affairs to Support Commercialization of EXXUA(TM)
DENVER, CO / ACCESS Newswire / June 25, 2025 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nerv...
Aytu BioPharma Expands and Extends Lending Agreement with Eclipse Following Agreement to Commercialize First-in-Class Antidepressant EXXUA(TM)
Term loan maturity extended by 12 months to June 2029 Principal balance on term loan expanded to $13.0 million from $11.1 million currently Expanded revolving line of credit facility by $1.5 million E...